FindTrial
Sign In

zilucoplan (RA101495)

DRUG7 trials

Sponsors

Ra Pharmaceuticals, Ra Pharmaceuticals, Inc., UCB Biopharma SRL

Conditions

Generalized Myasthenia GravisMyasthenia Gravis, GeneralizedParoxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
CompletedNCT03030183
Ra PharmaceuticalsParoxysmal Nocturnal Hemoglobinuria (PNH)
Start: 2017-04-17End: 2018-03-28Updated: 2022-07-27
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
CompletedNCT03078582
Ra PharmaceuticalsParoxysmal Nocturnal Hemoglobinuria (PNH)
Start: 2017-03-08End: 2018-03-28Updated: 2022-07-27
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
TerminatedNCT03225287
Ra Pharmaceuticals, Inc.Paroxysmal Nocturnal Hemoglobinuria (PNH)
Start: 2017-07-17End: 2021-10-26Updated: 2023-09-28
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
CompletedNCT03315130
Ra PharmaceuticalsGeneralized Myasthenia Gravis
Start: 2017-10-11End: 2020-11-19Updated: 2022-07-27

Phase 3

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
CompletedNCT04115293
Ra Pharmaceuticals, Inc.Myasthenia Gravis, Generalized
Start: 2019-09-17End: 2021-12-30Updated: 2025-07-16
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
CompletedNCT04225871
UCB Biopharma SRLGeneralized Myasthenia Gravis
Start: 2019-12-23End: 2026-07-31Updated: 2026-08-12
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
CompletedNCT05514873
UCB Biopharma SRLGeneralized Myasthenia Gravis
Start: 2022-10-31End: 2024-10-23Updated: 2025-09-03

Related Papers

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study
Therapeutic Advances in Neurological Disorders2025-07-051 citations
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
Journal of Neurology2025-06-126 citations
P.107 Early and sustained response over time with zilucoplan in generalised Myasthenia Gravis: 120-week post hoc analysis of RAISE-XT
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2025-06-01
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study.
2025-05-16
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Therapeutic Advances in Neurological Disorders2024-08-01
P.054 Long-term safety and efficacy of zilucoplan in myasthenia gravis: additional interim analyses of RAISE-XT
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2024-05-23
P.055 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: Interim analysis of RAISE-XT
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2024-05-23
Long-term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT (S15.002)
Neurology2024-04-09
Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
2024-02-247 citations
Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov.
2024-01-243 citations
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
Therapeutic Advances in Neurological Disorders2024-01-0127 citations
RAISE-XT: interim analysis of an open-label extension study of zilucoplan in patients with myasthenia gravis
2023-11-01
Subgroup outcomes from RAISE: a randomised, Phase 3 trial of zilucoplan in generalised myasthenia gravis
2023-11-01
Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the phase III randomized <scp>RAISE</scp> study
Clinical and Experimental Neuroimmunology2023-09-153 citations
2603 Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis
2023-08-01
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
2023-05-01143 citations
Subgroup outcomes from RAISE: A randomized, Phase 3 trial of zilucoplan in generalized myasthenia gravis (P1-5.006)
Neurology2023-04-251 citations
RAISE-XT: An interim analysis of safety and efficacy in an open-label extension study of zilucoplan in patients with myasthenia gravis (P1-5.007)
Neurology2023-04-251 citations
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
JAMA Neurology2020-02-17175 citations